A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Tavolimab (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 26 Jan 2018 Planned End Date changed from 29 Nov 2023 to 10 Jan 2024.
- 26 Jan 2018 Planned primary completion date changed from 22 Mar 2021 to 3 May 2021.
- 20 Oct 2017 Planned End Date changed from 25 Apr 2023 to 29 Nov 2023.